A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

ClinicalTrials.gov ID: NCT05137054

Public ClinicalTrials.gov record NCT05137054. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 10, 2026, 12:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma

Study identification

NCT ID: NCT05137054
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Regeneron Pharmaceuticals; Industry
Enrollment: 317 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Bortezomib Drug
Carfilzomib Drug
Cemiplimab Drug
Cevostamab Drug
Daratumumab Drug
Fianlimab Drug
Isatuximab Drug
Lenalidomide Drug
Linvoseltamab Drug
Nirogacestat Drug
Pomalidomide Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 16, 2022
Primary completion: Apr 10, 2028
Completion: Sep 25, 2034
Last update posted: Jan 21, 2026

2022 – 2034

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 12

Facility	City	State	ZIP	Site status
Scripps Clinic Torrey Pines	La Jolla	California	92037	Recruiting
Winship Cancer Institute of Emory University	Atlanta	Georgia	30004	Recruiting
Indiana University Health Simon Cancer Center	Indianapolis	Indiana	46202	Recruiting
Dana Farber/Harvard Cancer Center	Boston	Massachusetts	02215	Recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
Mayo Clinic	Rochester	Minnesota	55905	Recruiting
Weill Cornell Medicine/New York Presbyterian Hospital	New York	New York	10021	Recruiting
New York Presbyterian Hospital Columbia University Medical Center	New York	New York	10032	Recruiting
University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599	Recruiting
Wake Forest University Health Sciences	Winston-Salem	North Carolina	27157	Recruiting
The Ohio State University James Cancer Hospital	Columbus	Ohio	43210	Recruiting
University of Texas Southwestern	Dallas	Texas	75390	Recruiting
VA Puget Sound Health Care System	Seattle	Washington	98108	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05137054, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 21, 2026 · Synced May 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05137054 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →